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G. Schackert12, J. C. Tonn13, U. Schlegel14, H.-J. Steiger15, W. Wick16,17, R. G. Weber18, M. Weller7† and M. Loeffler6†
Abstract
Background: Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, many of which
eventually transform into a more aggressive type. LGG is characterized by widespread genetic and transcriptional
heterogeneity, yet little is known about the heterogeneity of the DNA methylome, its function in tumor biology,
coupling with the transcriptome and tumor microenvironment and its possible impact for tumor development.
Methods: We here present novel DNA methylation data of an LGG-cohort collected in the German Glioma
Network containing about 85% isocitrate dehydrogenase (IDH) mutated tumors and performed a combined
bioinformatics analysis using patient-matched genome and transcriptome data.
Results: Stratification of LGG based on gene expression and DNA-methylation provided four consensus subtypes.
We characterized them in terms of genetic alterations, functional context, cellular composition, tumor microenvironment
and their possible impact for treatment resistance and prognosis. Glioma with astrocytoma-resembling phenotypes
constitute the largest fraction of nearly 60%. They revealed largest diversity and were divided into four expression
and three methylation groups which only partly match each other thus reflecting largely decoupled expression and
methylation patterns. We identified a novel G-protein coupled receptor and a cancer-related ‘keratinization’ methylation
signature in in addition to the glioma-CpG island methylator phenotype (G-CIMP) signature. These different signatures
overlap and combine in various ways giving rise to diverse methylation and expression patterns that shape the glioma
phenotypes. The decrease of global methylation in astrocytoma-like LGG associates with higher WHO grade, age at
diagnosis and inferior prognosis. We found analogies between astrocytoma-like LGG with grade IV IDH-wild type tumors
regarding possible worsening of treatment resistance along a proneural-to-mesenchymal axis. Using gene signature-
based inference we elucidated the impact of cellular composition of the tumors including immune cell bystanders such
as macrophages.
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Conclusions: Genomic, epigenomic and transcriptomic factors act in concert but partly also in a decoupled fashion what
underpins the need for integrative, multidimensional stratification of LGG by combining these data on gene and cellular
levels to delineate mechanisms of gene (de-)regulation and to enable better patient stratification and individualization of
treatment.
Keywords: Glioma, Molecular subtypes, DNA methylation, Epigenetics, Astrocytoma, Tumor microenvironment, Cellular
composition, Prognosis
Introduction
Diffuse WHO grade II and III glioma (in short lower grade
glioma, LGG) describe an almost fatal disease of young
adults. These tumors share a more indolent course com-
pared with high-grade IV gliomas (glioblastoma, GBM).
Recent work has proposed a classification of glioma based
mainly on two genetic markers, namely absence or pres-
ence of isocitrate dehydrogenase 1 and 2 (IDH) mutation
and of codeletion of chromosome arms 1p and 19q
(codel), overriding histology [14, 37, 45, 56, 66]. IDH-mut
codel tumors with mostly oligodendroglial histology are
associated with the best prognosis; IDH-mut non-codel
tumors with mostly astrocytic histology are associated
with intermediate outcome; and IDH-wt, with mostly
higher WHO grade (III or IV) tumors are associated with
poor prognosis [51, 65]. Besides genetic factors (DNA-)-
methylation has emerged an important regulator of gene
transcription, and its role in tumorigenesis has become a
topic of considerable interest [11, 33]. A number of stud-
ies have reported alterations of DNA methylation in gli-
omas [6, 7, 9, 12, 31, 35, 38, 47, 55].
IDH mutations occur early in gliomagenesis in the vast
majority of WHO grade II and III gliomas. They change
the function of the IDH enzymes, causing them to pro-
duce 2-hydroxyglutarate (2HG), an oncometabolite that
represses DNA demethylation [63] and, in consequence,
leads to genome wide DNA-hypermethylation subsumed
as glioma-CpG island methylator phenotype (G-CIMP)
[47]. Whole genome methylation studies have revealed
that G-CIMP gliomas split into subgroups differing in
the Chr. 1p/19q codeletion status and the total level of
methylation [8] where decreased methlylation associates
with worse survival and increased risk for recurrence
[12] and possibly reflects a global DNA demethylation
shift of progressing G-CIMP-tumors. Both, genetic and
epigenetic events can drive progression of gliomas lead-
ing to nearly identical phylo (epi-)genetic relations [40].
Moreover, recent studies reported continuous pheno-
typic drifts along a proneuronal-to-mesenchymal axis in
IDH-wild type GBM associated with increasing therapy
resistance that contradict a major role of genetic aber-
rations as drivers of essential tumor characteristics such
as resistance [54] and that are linked to drifts in DNA
methylation [32] and the cellular composition of the
tumor microenvironment [62]. We ask if similar mecha-
nisms can be identified also in IDH mutated LGG.
In general, deregulation of cell functions in cancer is
encoded in both the genome and epigenome which un-
derscores the importance of epigenetic analyses in paral-
lel to the discovery of transcriptomics and genetics.
Current analyses have not yet clarified the relationships
between the methylome and transcriptome. In LGGs
about 84% of all cases carry IDH-mutation with about
35% of them carrying an additional Chr. 1p/19q-codele-
tion, which enables studying phenotypic variability of
the transcriptomes and methylomes especially of these
genomic strata.
Our previous expression profiling of grade II and III pri-
mary glioma from a prospective German Glioma Network
(GGN) cohort revealed rich heterogeneity of their tran-
scriptomes which were only partially linked to the gen-
omic features [65]. For this study transcriptomic and
genetic data of the 137 lower grade glioma samples from
the GGN cohort were complemented by new (DNA-)
methylation data of 122 matched tumors of the same co-
hort which enables a combined analysis aimed to study
DNA methylation as a shaping factor of glioma hetero-
geneity. Here we perform molecular subtyping which has
emerged as an important concept to describe glioma het-
erogeneity and to better understand the biology of this
devastating disease. We show that genomic, transcrip-
tomic and methylation data provide partly overlapping
but also distinct molecular subgroups, suggesting that dif-
ferent omics-views provide complementary and partly in-
dependent information about modes of gene-regulation
[26, 57] with potentially different prognostic and thera-
peutic relevance. We aimed at characterizing the func-
tional context of these different modes with special
emphasis on the cellular composition of the tumors and
their microenvironment and on possible impact for tumor
development from lower grade to higher grade gliomas.
Materials and methods
Patients, tumors and data
The GGN study of WHO grade II or III gliomas (LGG)
was described previously [65]. For this previous study,
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we had analyzed tumors of 137 patients by array-CGH,
Affymetrix chip-based gene expression and candidate
gene analyses (see [65] and Additional file 1: Figure S1).
All tumors were subjected to central pathology review
and classified according to the 2016 WHO classification
of tumors of the central nervous system [37]. For the
present study, molecular characterization was supple-
mented by array-based DNA methylation data (Illumina
450 K arrays) of 122 patient-matched tumors of the
GGN cohort (Additional file 2: Table S1).
Expression, CGH data and DNA methylation analyses
Expression and array CGH data were processed as de-
scribed in [65]. For genome-wide assessment of DNA
methylation glioma samples were arrayed using the Illu-
mina HumanMethylation450 BeadChip according to the
manufacturer’s instructions at the DKFZ as described
previously [55]. A verification set of WHO grade II and
III gliomas was taken from the TCGA repository
including gene expression and DNA methylation data
(Additional file 3: Table S3). Gene expression data were
corrected for background noise, calibrated, quantile-nor-
malized and transformed into log10-scale, as described
in [65]. CpG IDs were mapped to the promoter region
of each gene ranging from 2 kb upstream to 200 bp
downstream of the transcription start site using RefSeq
mRNA annotation. DNA methylation beta-values of the
respective CpGs were averaged to get one mean methy-
lation beta-value for each gene promoter available.
Genes located on Chr. X and Y were excluded from
analyses. For an alternative analysis we also integrated
CpG methylation over enhancer and gene body regions
(see below).
Bioinformatics analysis
Gene expression and DNA methylation data were cen-
tralized and then analyzed after dimension reduction to
metagenes using self-organizing map (SOM) machine
learning [67]. As a result, each tumor tissue is character-
ized by the expression/methylation values of 2500/900
metagenes. Downstream analysis tasks including class
discovery, visualization and knowledge mining using
gene set analysis were performed with the R-package
‘oposSOM’ [36]. Unsupervised class discovery of expres-
sion and methylation subgroups was performed inde-
pendently in metagene space by using maximum
spanning graph-partitioning [65] followed by iterative
maximization of the sample similarity score until con-
vergence as described before [34]. For gene set profiling
we applied the gene set Z-score (GSZ) metrics to esti-
mate the mean differential expression of the set genes in
each sample compared with their mean expression levels
averaged over all samples in units of the respective
standard deviation [58]. We considered gene sets related
to biological processes (BP), of the gene ontology (GO)
classification, and standard literature sets and literature
sets curated by our group [68]. Immune cell compos-
ition of the tumor biopsies were estimated from the ex-
pression data using the program CIBERSORT [46].
Results
WHO grade II/III gliomas split into eight expression and
six methylation subtypes
Single data type class discovery of gene expression data
of 137 WHO grade II/III gliomas and DNA methylation
data of patient-matched samples all collected in the Ger-
man Glioma Network (GGN) provided eight expression
subtypes designated as E1 – E8 (E-groups) and six
methylation subtypes (M1 – M6, M-groups, Fig. 1a).
The subtypes E1 and M1 nearly completely collect
IDH-wild type tumors mostly with gains on Chr7 and
losses of Chr10 representing genetic hallmarks of glio-
blastomas [5, 51, 65] (Fig. 1b, Additional file 1: Figure S2
and Additional file 1: Table S4 and Additional file 1:
Table S5 for sample counts and enrichment analysis).
The subtypes E2 – E6 and M2 – M5 nearly exclusively
contain IDH mutated tumors predominantly without
codeletions on Chr1p and Chr19q as genetic hallmarks
of astrocytomas while the subtypes E6 and M5 strongly
enrich samples with a codeletion on Chr1p and Chr19q
as a genetic hallmark of oligodendrogliomas [37]. Gains
on Chr7 that are not paralleled by losses on Chr10 are
frequently found in E4 and M3 (Additional file 1: Figure
S2). A chromosome map of gene expression reveals
dose-response effects of all these chromosomal defects
(Additional file 1: Figure S3A). We find a relatively high
number of aberrations in E2 and a relatively small one
in E7/M6 and E5/M4 (Fig. 1b and Additional file 1:
Figure S2). Interestingly, a bimodal differential methyla-
tion pattern between M1 – M3 (reduced methylation)
and M4 – M6 (increased methylation) is detected for
the olfactory subgenome [19] which collects genes en-
coding G-protein coupled receptors (GPCR’s) especially
on Chr11 (Additional file 1: Figure S3B). The E-groups
do not show this clear separation into two entities al-
though the amount of hypomethylated GPCR’s increases
progressively from E7 to E1 (Additional file 1: Figure
S3B). A similar bimodal methylation patterns is found
for gene clusters encoding keratin intermediate filament
proteins on Chr12 and Chr17 in the M-groups
(Additional file 1: Figure S3B). We compared the mean
methylation levels of the promoter regions as used
throughout this work with those of enhancer and gene
body regions and found similar methylation patterns on
average (Additional file 1: Figure S4), which suggests that
aberrant methylation affects widespread genomic regions.
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Fig. 1 Characteristics of molecular subtypes of glioma. Samples were grouped into gene expression groups E1 – E8 (E-classes) or DNA
methylation groups M1 – M6 (M-classes) using the sample expression and methylation data, respectively. A) The pairwise sample correlation
heatmaps visualize the correlation coefficient between all pairwise combinations of sample-portraits. Intra-class similarities between samples are
evident as brown quadratic areas along the diagonal while inter-class relations are seen either as brown or blue off-diagonal regions for positively
and negatively correlated data landscapes, respectively. B) Genetic, methylation and clinical characteristics (see text). C) We sorted samples in each
E-group according to their M-group membership and in each M-group according to their E-group membership to better recognize pattern due to
methylation and expression effects, respectively (see the two color bars above the heatmap). The color code for molecular groups are used
throughout the paper. Mutual relations between the E- and M-groups were estimated based on mutual memberships of the samples giving
rise to four consensus subtypes C1- C4 which are characterized by IDH-wild type astrocytoma-like (IDH-wt), IDH-mutated astrocytoma-like
(IDH-A) and oligodendroglioma-like (IDH-O) and a neuronal-like (NL) phenotypes, respectively
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Consensus subtypes assign to astrocytoma-like,
oligodendroglioma-like and neural phenotypes
Detailed analysis of the distribution of samples among the E-
andM-subtypes reveals large overlap of tumors and thus cor-
respondence between E1 and M1, E6 and M5 and also
between E7 andM6 (Fig. 1c) while E2 – E5 intermix withM2
– M4 with partial correspondence between E3 and M2.
Based on these results we define the consensus classes C1 –
C4 where C1, C3 and C4 represent classes with almost
one-to-one mutual correspondence between the expression
andmethylation subtypes.With a nearly exclusive content of
IDH-wild type tumors in C1 (100% in E1 and 87.5% in M1)
and of IDH-mutated andChr1p/19q codeleted tumors in C3
(92% in E6 and 100% in M5) these subtypes show clear gen-
etic characteristics that assign them to expression and
methylation phenotypes of IDH-wild type astrocytoma-like
(IDH-wt) and to oligodendrogioma-like (IDH-O) resem-
blance, respectively [37]. In contrast, C2 is a more heteroge-
neous group regarding the correspondence between the E-
and M-classes. It collects predominantly IDH mutated tu-
mors (more than 97% in C2) almost always without Chr1p/
19q codeletions (85% for E-groups and 90% for M-groups)
and without alterations on Chr7 and Chr10 (95%) (see also
Additional file 1: Table S4) which assigns C2 to gliomas of
IDH-mutant astrocytoma-like resemblance (IDH-A) [37].
Nevertheless, a minority of about 15% of all IDH-mutant and
Chr.1p/19q codeleted oligodendrogliomas are in C2 (12.5%
in the E-groups and 17% in theM-groups) mostly because of
a decreased methylation level of the GPCR subsumed in the
olfactory subgenome that contrasts them compared with the
majority of 67% oligodendrogliomas in C3/IDH-O (60% in
E6 and 75% in M5) and also in C4 (15% / 8%, Additional file
1: Figure S3B). The consensus subtype C4 collecting E7, E8
and M6 constitutes mixtures of tumors with genetic charac-
teristics present in all remaining subtypes. We assign speci-
mens with reduced tumor cell content to C4 based on the
observations that the mean number of copy number aberra-
tions on Chr7 and Chr10 in E1 and on Chr1p and Chr19q in
E6 is reduced for samples in E7, respectively (Additional file
1: Figure S5). Additionally, C4 shows a healthy brain func-
tional context, e.g. related to synaptic transmission (see
below). Hence, the expression andmethylation landscapes of
the glioma subtypes are shaped in first instance by the under-
lying key genetic defects in agreement with a recent classifi-
cation of LGGs [56]. However, we also found a large degree
of inter-tumoral heterogeneity of expression and methyla-
tion phenotypes that considerably modulates this genetic
picture as illustrated by means of sample-similarity nets
based either on the gene expression or on the methylation
data (Additional file 1: Figure S7). This uncertainty obviously
results, among other factors (such as tumor purity and com-
position), from themultidimensional nature of the transcrip-
tomes and methylomes, e.g. from the combination of
different G-CIMP- and GPCR-methylation patterns, from
the lack of a clear-cut one-to-one relation between many of
these phenotype-dimensions and the underlying genotypes.
The subtypes differ in overall promoter methylation,
WHO grade and prognosis
Next, we compared the mean absolute promoter methy-
lation level averaged over all genes and samples of each
subtype (Fig. 1). It is low in C1 (IDH-wt) and high in C3
(IDH-O) and also C2 (IDH-A), as expected, because
these predominantly IDH-mutated tumors in C2 and C3
form the CpG hypermethylation phenotype (G-CIMP)
[47]. The degree of hypermethylation in M2 is reduced
compared with the other IDH mutated tumors in C2
and C3 while promoter methylation is on intermediate
level in C4 collecting a mixture of IDH-mutated (64%)
and IDH-wt (36%) tumors. Interestingly, the mean
methylation level of the subtypes inversely relates to
their overall survival hazard ratio (Additional file 1:
Figure S6). Worst prognosis of IDH wild type LGG com-
pared with IDH mutated and Chr1p/19q codeleted (best
prognosis) and non-codeleted ones (intermediate prog-
nosis) was reported previously [65]. Interestingly, we
find a similar, however more subtle inverse trend be-
tween methylation and HR in the E- and M-groups col-
lected in C2 (IDH-A) that associates with the
accumulation of WHO grade II astrocytic tumors in E4
(58%) and E5 (60%, decreased HR and increased methy-
lation, Additional file 1: Table S4) while grade III tumors
accumulate in E3 (100%) and E2 (71%, increased HR and
decreased methylation). Enrichment of higher tumor
grade III is also found in M2 (78%) and M3 (70%). It is
associated with worse prognosis and decreased
methylation (Additional file 1: Figure S6). Taken to-
gether, our data suggest associations between decaying
methylation, increasing WHO grade and HR in IDH mu-
tated astrocytoma-like tumors (IDH-A).
Verification using TCGA data and comparison with
previous signatures of gliomas
The E- and M-subtypes found here were confirmed (ex-
cept E5) in more than 270 LGGs taken from The Cancer
Genome Atlas (TCGA) using a guided SOM-extension
method that combines the GGN- and TCGA-data and
enables their joint analysis [34] (Additional file 1: Figure
S8, Figure S9). Moreover, we selected a series of GBM
and lower-grade glioma (LGG) signature gene sets of
previous classification schemes and compared them with
the subtypes identified herein (Fig. 2 and Additional file
1: Table S6). We found correspondence between our
subtypes E1 and partly E3 and signatures of the classical
(CL) and mesenchymal (ME) expression subtypes of
grade IV gliomas [60], of the pre-glioblastoma (PG) sub-
type of LGG [20] and of hypermethylated genes of the
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G-CIMP-phenotype [47]. Signature genes of proneural
(PN) GBM [60] and of early-progenitor-like (EPL) LGG
[20] show similarities with C2 (IDH-A), with subtle dif-
ferences between E2, E3 and E4, while neuronal GBM
(NL) and healthy brain signatures match to C4 and
partly C3 (IDH-O). Interestingly, E3 collects IDH-mu-
tated glioma with an inflammatory, mesenchymal-like
expression signature. The expression level of most of
these signatures sharply change between the E-groups
which indicates correspondence between our current
classification and those previously described. The ana-
lysis of gene sets derived from methylation studies pro-
vides analogous results where, e.g., hypermethylation
signatures in LGG [9] and the IDH subtype of GBM [55]
largely agree with the G-CIMP-profile [47] that shows
hypermethylation in M2 - M5 (Fig. 2). Oligodendroglial
glioma reveal a modified G-CIMP-profile (G-CIMP-O)
with enhanced methylation in M5 that closely resembles
the RTKII profile [55]. CpG-level marker sets confirm
the G-CIMP and G-CIMP-O profiles [49] (Additional
file 1: Figure S10). Interestingly, methylation signatures
of fetal and adult healthy brain [27] indicated strong
similarity with the GPCR-signature meaning that the re-
spective genes markedly lose methylation in gliomas, es-
pecially in M1 – M3. Overall, methylation signatures
from previous studies including those of grade IV GBM
[55] indicate similar underlying expression and methyla-
tion patterns. Accordingly, the consensus subtype C1
(IDH-wt) possesses pre-GBM (PG) characteristics, C2
(IDH-A) and C3 (IDH-O) are proneural-like (PN)
Fig. 2 Gene set analysis associates the E- and M-subtypes with previous glioma expression and methylation signatures (see Additional file 1:
Table S6 for details). The expression and methylation levels of the signature sets are shown as bar-code profiles where each bar refers to one
sample. Correlation plots between expression and methylation levels in GSZ-scale reflect predominantly repressive effects of promoter
methylation on the expression of the downstream genes (right part)
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tumors (with E3 showing more mesenchymal-like char-
acteristics) and C4 represents a neural-like (NL) subtype
with mixed genetic characteristics of gliomas and ex-
pression properties partly resembling those of healthy
brain in agreement with [62]. We also compared our
subtypes with the epigenetic classes of Ceccarelli et al.
[8] making use of CpG-level methylation and epigeneti-
cally regulated gene signatures (Additional file 1: Figure
S11) and of an extended GGN data set (Additional file 1:
Figure S13). Accordingly, M2 tumors reveal resemblance
with the GCIMP-low and M3 – M4 tumors with the
GCIMP-high classes of Ceccarelli et al. while C1 tumors
can be assigned to CL-like (8 cases) and ME-like (6
cases) glioma based on their expression characteristics
and to a 40/60% composition of RTKII and MS tumors
using their methylation signatures. Most interestingly,
the E3 tumors reveal characteristics of pilocytic astrocy-
tomas (PA) which was detected by comparison with the
expression patterns of 16 PA samples collected in the
GGN. PA-resemblance was established for IDH-wt gli-
omas by Ceccarelli and colleagues but not for IDH-mut
LGG. In summary, almost all E- and M- subtypes could
be verified in an independent dataset and by previous
glioma signatures where our approach stratifies
IDH-mut astrocytomas (C2) in a novel way into three
methylation and four expression subtypes which only
partly match each to another.
Functional context and epigenetic signatures
Next we analyzed the functional context of the E- and
M-subtypes of our data set (Fig. 3 and Additional file 1:
Figures S14- S16). Gene signatures reflecting highly prolif-
erating cells and high levels of oxphos metabolism are
strongly expressed in E1 and E6 but weakly expressed in
E7 which instead shows activated cell functions of healthy
brain such as synaptic transmission. Inflammatory re-
sponses and a signature of epithelial-mesenchymal transi-
tion (EMT) were high in E3 and to a lesser degree
observed in E1 but almost deactivated in C3 (IDH-O).
Profiling of a series of metabolic gene sets confirms high
oxphos and mitochondrial transcriptional activity in C3
paralleled by decreased glycolysis (Additional file 1:
Figure S15) while C2 (IDH-A) is characterized by gained
methylation and decreased expression of genes related to
fatty acid metabolism, oxphos and mitochondrial func-
tions. Interestingly, E2 seems metabolically deactivated
throughout all processes considered while C1 (IDH-wt)
shows the opposite trend.
Gene signatures of the ageing brain suggest parallels
with inflammatory signatures upregulated in E3/E4. The
methylation profiles of all these signatures show mostly
anti-correlated patterns compared with the expression
profiles (see the right ‘methylation’ part of Fig. 3a and
Additional file 1: Figure S14). It indicates that promoter
methylation predominantly represses transcription of the
respective downstream gene. Gene sets estimating the
activity of G-protein coupled receptors (GPCR), and of
keratinization both show binary methylation patterns
with low levels in M1 – M3 and higher levels in M4 –
M6 and correlated expression with the inflammatory sig-
nature and anti-correlated expression with the signature
of synaptic transmission. Signatures related to epidermal
cell differentiation and keratinization are prone to
hypo-methylation also in other cancers [71]. They are
found to tune the balance between stemness and som-
atic functions [28], to promote EMT-like processes [50]
and also can serve as prognostic markers in epithelial
cancers [30]. Testis-specific genes are overexpressed in
E5. This phenomenon is observed also in other cancers
[25] where so-called cancer testis (CT) genes often en-
code antigens that are thought to be immunogenic in
gliomas and particularly in cancer stem cells [16, 18, 73].
Interestingly, also signatures with impact for epigen-
etic mechanisms of gene regulation reflect pronounced
subtype-specific differences (Fig. 3a, part below).
Particularly, H3K4me3 marked genes in active pro-
moters of neural progenitor cells (NPC) [42] and tran-
scription factors (TF) associated with high expression
levels in a wide collection of cells [24] show low methy-
lation in M5 contrasted by high methylation in M1 and
partly in M2 and M3 and thus similar trends as observed
for the signatures related to highly proliferating cells and
MYC targets discussed above. This seems plausible for
M5 because highly proliferative cells require promoters
activated by demethylation while activation of prolifera-
tion genes in M1 requires another mechanism. In con-
trast, hypermethylation in C3 (IDH-O), and to a less
degree in C1 (IDH-wt) and C2 (IDH-A), is observed for
targets of the polycomb repressive complex 2 (PRC2) in
de-differentiated tumor cells [3], for related compounds
such as SUZ12 and EED targets and for bivalently
H3K4me3 and H3K27me3 marked genes in poised pro-
moter states that are enriched in tumor suppressors
[41]. Their suppression via hypermethylation promotes
cancer development in gliomas and in other cancer en-
tities [27]. The respective expression and methylation pro-
files closely resemble those of healthy brain and synaptic
transmission thus suggesting their suppression by epigen-
etics in gliomas. It is known that PRC2 is required for
neuron specification during differentiation and for sup-
pression of a transcriptional program that is detrimental
to adult neuron function and which in case of PRC2 defi-
ciency leads to neurodegeneration via de-repression of bi-
valent PRC2 target genes [61, 70]. An analysis of genes in
a set of defined chromatin states [15] determined in
healthy fetal and adult brain tissues representing different
states of brain development [52] further supports the view
that suppressor-mechanisms in cellular programs are
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Fig. 3 Gene set analysis of functional and epigenetic signatures: a Bar-code profiles of expression and methylation levels of functional and epigenetic
signatures and the correlation plots of subtype averaged values (see legend of Fig. 2). b Schematic overview about the basic functional, genetic and
glioma characteristics extracted from the gene-signature analysis
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related to brain development and that genes in repressed
states with impact for brain differentiation become hyper-
methylated in G-CIMP-subtypes and especially in C3
(Additional file 1: Figure S17).
Detailed functional analysis reveals anti-concerted al-
terations of expression and methylation, which associate
with transcriptional activation of cell cycle related bio-
logical processes and the decay of neuronal processes
such as synaptic transmission especially in C1 and C3
and also with changes of inflammatory characteristics in
C2 (Additional file 1: Figure S18). Overall we identified
three combined expression-methylation patterns
(Additional file 1: Figure S19), namely (i) activating modes
were related to proliferation and show increased expres-
sion which however associates either with increased (C1/
IDH-wt) or decreased (C3/IDH-A) methylation reflecting
different driving mechanisms; (ii) deactivating modes
which combine decreased expression and increased
methylation in all subtypes associated with functions such
as synaptic transmission; and (iii) functions related to im-
mune response also showing anti-correlated changes be-
tween expression and methylation but an activating effect
in C1 and especially E3 and deactivating effect in C3.
Hence, degeneration of healthy brain functions in all sub-
types, activated proliferation in C3 (IDH-O) and partly in-
flammation in E3 seem to be affected by anti-correlated
DNA-promoter-methylation changes. In summary, the
subtypes were characterized by combined alterations of
the methylation and expression levels of genes from cellu-
lar programs such as proliferation, energy metabolism, im-
mune response and synaptic transmission which associate
with repressed and poised chromatin states in healthy
brain and their subtype-specific remodeling in gliomas
(Fig. 3b).
Reference to single cell signatures disentangles glioma
cell types
Gliomas are composed of neoplastic and non-neoplastic
cells, each of which potentially contribute to cancer for-
mation, progression and response to treatment [22, 62].
Bulk expression and methylation profiles as analyzed in
this work average the diverse cell signatures within each
tumor, thereby potentially masking critical differences
and providing limited insight into cancer cell programs
and the effect of the tumor microenvironment (TME).
To disentangle this heterogeneity on cellular and TME--
levels, we evaluated the expression and methylation de-
gree of a collection of gene signatures taken from recent
single cell RNAseq experiments on gliomas [59] in our
data (Fig. 4a). We find that C2 gliomas were characterized
by relatively high expression levels of benign astrocytes
(astro-program, especially in E4), malignant astrocyte-like
cells (IDH-A signature) and of microglia/macrophages
(especially in E3) which all confirm the astrocyte-like
phenotype of C2. On the other hand, these signatures are
all low in C3 tumors which instead show activated expres-
sion of oligodendrocyte-like cells (oligo-program and
IDH-O signatures), of stemness and of neuronal signature
genes where the latter ones are also high in C4 (neural
subtype). The expression characteristics associate with al-
most mirror symmetrical methylation profiles showing ei-
ther G-CIMP- or anti-G-CIMP characteristics, thus again
suggesting regulatory effects of gene promoter methyla-
tion on downstream gene expression. A more detailed
analysis indicates anti-correlated expression and methyla-
tion patterns of the malignant IDH-A and IDH-O dimen-
sions suggesting that neoplastic transformations in IDH-O
and IDH-A cells are driven by de-methylation of the re-
spective signature genes while cell cycle and microglia/
macrophage signatures increase and neuronal, healthy
astro- and oligo-program signatures decline with increas-
ing grade (Additional file 1: Figure S20). Overall, C3 tu-
mors share closer similarities with healthy brain functions
than C2-gliomas. C2-tumors instead show enhanced ex-
pression of macrophages/microglia signatures where
microglia are crucial immune cells of the central nervous
system and serve as tissue-resident macrophages of the
brain [53]. On the other hand, both, C2 (IDH-A) and C3
(IDH-O) tumors are more proliferative compared with
neuronal ones (C4). A higher amount of microglia/macro-
phage cells in astrocytoma and an increasing amount of
proliferating cells is known to be a hallmark of higher
grade gliomas [22]. In summary, the single cell character-
istics reflect the variability of the composition of the tu-
mors regarding healthy and benign astrocyte- and
oligodendrocyte-like cells, microglia/macrophage and pro-
liferative stem cell-like constituents in the bulk specimens
studied.
mRNA inferred immune cell components
To further characterize the TME we employed CIBER-
SORT [46], a computational cell-type deconvolution
method that decomposes the glioma-associated stroma
into its immunological cellular components using
cell-type related expression signatures (Fig. 4b and
Additional file 1: Figure S21). We find that
M2-macrophages are highly abundant in the astrocytic
groups E1 – E4 with highest levels in E3 and E2 opposed
by a reduction in monocytes. M2-macrophages play a
pro-tumoral and anti-inflammatory role in brain cancer;
they promote tissue remodeling and tumor growth [13,
53], particularly in glioma [43], and associate with
resistance to radiotherapy in mesenchymal glioblastoma
[62]. In contrast, anti-tumoral and pro-inflammatory
M1-macrophages are almost absent in all grade LGG sub-
types except for the pre-GBM subtype E1. Beyond a dual
M1/M2 polarization status, a continuum between M1 and
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M2 polarization seems to exists in glioma [17] including
IDH-mut tumors [59] which provides a possible interpret-
ation of the increasing M2 percentage in C2 from E5 to E3.
It has been hypothesized that the most aggressive and inva-
sive cells in GBM are neoplastic macrophages arising in fu-
sion hybrids between neoplastic stem cells and
macrophages/microglia [29]. The high M2-macrophage
abundance in astrocytic gliomas is paralleled by relatively
large percentages of neutrophils while increased abundance
of M1-macrophages in E1 is accompanied by CD4-resting
memory T-cells. The amount of tumor infiltrating CD4+ leu-
kocytes in glioblastoma correlates with tumor progression
and presumably relates to tumor angiogenesis [23, 44]. We
also found that activated mast cells are relatively abundant in
virtually all groups (especially in E4, E5 and E7) except E1.
Mast cells were shown to become recruited and ‘educated’
by glioma cells in a glioma grade-dependent manner to re-
duce stemness, decrease proliferation and migration to in-
duce differentiation of glioma cells [1]. This mechanism
seems to apply to early tumor stages of IDH-mutated
astrocytoma-like gliomas (C2). Interestingly, regulatory
T-cells (Tregs) show increased percentage in the
oligodendroglioma-like subtype C3, the subtype with lowest
immune and inflammatory characteristics, which is in cor-
respondence with the immunosuppressive role of Tregs in
glioma [48]. We also make use of immune cell gene signa-
tures taken from [4] to compare their expression andmethy-
lation levels (Additional file 1: Figure S21).We find that most
of them show high expression especially in E3 and E1 reflect-
ing their accumulation in higher grade astrocytoma. These
expression profiles are mostly paralleled by G-CIMP and es-
pecially G-CIMP-O methylation profiles which suggest de-
activation of immune cell activities in C3 by DNA
methylation. Interestingly, the methylation profile of T-cells
resembles that of GPCR, which suggests a cell specific rela-
tion between DNAmethylation and gene expression. Hence,
the changes of methylation observed originate from both gli-
oma and immune cells, which suggests coupled epigenetic
mechanisms during tumor development. Note that DNA
methylation in glioma bulk samples was found to be predict-
ive for immune cell infiltration [32]. In summary, digital im-
mune cell deconvolution of the transcriptome reveals that
M2-macrophages were enriched in higher grade astrocyto-
mas (E1- E3) while activatedmast cells are more abundant in
the neuronal subtype (C4), in lower grade astrocytomas
(E4- E5) and in oligodendrogliomas (E3) together with
immunosuppressive Tregs. Hence, the TME is characterized
by marked variations of the immune cell composition that
overlays with methylation changes of their genomes which
suggests an epigenetically-mediated interplay between devel-
opment of tumor cells and immune cells in theTME.
Treatment resistance and senescence signatures associate
with methylation
Next, we studied a 50-gene multi-therapy resistance signa-
ture, which reflects a continuum of cell phenotypes with in-
creasing resistance against chemo- and radiotherapy
paralleled by a proneural-to-mesenchymal shift of their tran-
scriptomes [54]. In our data, we find a profile of this signature
showing highest expression in E3 (C2) and C1 and lowest in
C3 (Fig. 4c), thus suggesting a gradient of treatment resist-
ance from oligodendroglioma-like to astrocytoma-like tu-
mors with inflammatory characteristics of the TME. The
resistance signature resembles the profiles of inflammatory
and EMT functional signatures (Fig. 3a) and that of the mes-
enchymal GBM-subtype (Fig. 2a) in our data. Tumors of the
latter type indeed showed enhanced treatment resistance
[32, 54, 62]. The methylation profile of the resistance signa-
ture reflects G-CIMP characteristics and anti-correlates with
the respective expression levels, which suggest a
methylation-driven repression mechanism. Interestingly, the
methylation profile of the resistance signature strongly corre-
lates with the total methylation level of the tumors (R2 > 0.9),
which suggests that treatment resistance associates with
overall methylation of the tumors. Our data support the view
that the methylation profile of the signature anti-correlates
with the HR-profile (R2 < -0.7, compare also with Fig. 1)
showing that worsening of prognosis of astrocytoma-
like IDH-mutated tumors (C2/IDH-A) associates with
de-methylation of the tumors. A GCIMP-low methylation
profile, mesenchymal-like expression characteristics and
genomic instability was recently found in recurrent gliomas
[12] in analogy with the characteristics of M2/E3-tumors re-
ported here (Additional file 1: Figure S2, Figure S12).
A recent model of glioma progression suggests that
increased senescence bypass mechanisms proceed in par-
allel with tumor development and the formation of a
pro-inflammatory microenvironment at later phases [2].
We, therefore, studied a signature of genes that contribute
to senescence bypass mechanisms by promoter-
hypermethylation during aging and tumorigenesis and
which associate with cancer risk [69]. These genes become
(See figure on previous page.)
Fig. 4 Cell type, micro-environmental immune cell and treatment-resistance characteristics. a Heatmaps of expression and methylation levels of
single-cell signatures taken from [59] reveal subtype-specific activation of astrocyte-, oligodendrocyte- and stem cell-like characteristics. b Digital
immune cell-type decomposition of glioma transcriptomes using CIBERSORT [46] (see Fig. S21 for the full set of cells considered) on sample (above)
and mean subtype levels for selected leukocyte cells across the expression subtypes. c The boxplots of expression and methylation levels of a
transcriptomic drug and radiation resistance signature containing 50 genes [54] suggest largest resistance effects in E3 and E1. Expression and
methylation levels of the subgroups anti-correlate (right part)
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increasingly deactivated in the tumors of the E-groups
from E7 to E1, i.e. along the neuronal- proneural to mes-
enchymal axis (Additional file 1: Figure S23). Their senes-
cence profile resembles those of the PRC2-targets,
RTKII-characteristics, ageing and healthy brain signatures,
while the methylation profiles of the two latter signatures
differ from the former ones regarding methylation of
Chr1p/19q-codeleted tumors in C3. Particularly, these
tumors show increased methylation of senescence genes
accompanied by demethylation and transcriptional upreg-
ulation of genes involved in oxphos-metabolism (Fig. 3
and Additional file 1: Figure S15) and/or deactivated
inflammatory response. It is assumed that Chr1p/19q-
codeleted gliomas (C3) bypass senescence by other mech-
anisms than Chr1p/19q-non-codeleted tumors [2].
Overall, the LGG-subtypes group along a therapy-resist-
ance signature suggesting that resistance and recurrence
are mediated by epigenetics and an inflammatory
TME along the proneural mesenchymal-like axis also
in LGG accompanied by graded loss of methylation
and increased CNV and IDH-wt resemblance. More-
over, astrocytoma-like tumors in C2 seem to develop
along this axis as indicated by progressive activation
of senescence bypass mechanisms.
Discussion
Heterogeneity of WHO grade II and III gliomas
Our multi-platform transcriptome-methylome-genome
study revealed a large molecular heterogeneity of adult
diffuse gliomas of WHO grades II and III: we identified
eight expression and six methylation subtypes and charac-
terized them in terms of genetic aberrations, functional
context, cellular composition, tumor microenvironment
and their possible impact on treatment resistance and
prognosis as illustrated in the summary scheme in Fig. 5.
The expression and methylation patterns of the glioma
subtypes are shaped by the underlying key genetic defects
in agreement with recent classifications of LGG [8, 45,
56]. Overall, we identified three consensus subtypes
C1-C3 that were assigned as IDH-wt and IDH-mut
astrocytoma-like and oligodendroglioma-like phenotypes
according to their dominating genetic status in terms of
the IDH mutation and Chr. 1p/19q codeletion. These gen-
etic aberrations are assumed to act as early events of
tumorigenesis [64] (see left part of Fig. 5a). A fourth, neur-
onal subtype (C4) collects specimen with reduced tumor
cell content and served as reference partly resembling
characteristics of healthy brain. However, our subtypes re-
flect also a large variability of expression and methylation
phenotypes that do not match the genetic hallmarks in a
one-to-one fashion. For example, 25–40% of all IDH-mut
and 1p/19q-codel tumors were not assigned to the
oligodendroglioma-like subtype (C3) but rather resemble
the astrocytoma-like (C2) or neuronal (C4) types by a
series of features. This heterogeneity results, among other
possible factors, from the multidimensional nature of the
transcriptomes and methylomes of the tumors. Each of
their expression and methylation landscapes can be inter-
preted as a superposition of different expression and
methylation patterns, which associate with specific cellular
and micro-environmental states, and which obviously lack
a clear-cut relation with respect to the underlying geno-
types. The astrocytoma like gliomas constitute the largest
fraction of nearly 60% of all LGG studied. They revealed
the largest diversity and were divided into four expression
(E2-E5) and three methylation (M2-M4) subtypes, which
only partly match each other, thus reflecting partly
decoupled expression and methylation patterns due to dif-
ferent possible interaction mechanisms [26, 57]. Particu-
larly, decoupling between transcription and methylation
can be rationalized in terms of independent regulation
mechanisms of transcription by epigenetic and transcrip-
tion factor (TF)-networks which are governed by bistable
epigenetic switches [57]. Applying this model to cell differ-
entiation data we recently identified situations where vari-
ant transcription of genes is accompanied by invariant
epigenetic promoter states or vice versa. Interestingly, the
former situation of TF-dominated regulation seems to
apply to elementary cell functions related to stress
response, cell cycle regulation and cell metabolism and re-
quires mostly high expression levels of the genes beyond
the sensitivity range of the switches. Combined regulation
is found for developmental processes where genes become
activated or deactivated by epigenetics, usually via histone
methylation changes associated with DNA-hypo- or –
hypermethylation near their promoters. Changes of methy-
lation with only minor effect on transcription was found
for GPCRs also upon cell differentiation. Overall we find
striking agreement between gene functions in these three
regimes between cell developmental data [57], WHO grade
IV GBM [26] and the LGG studied here. Interestingly,
methylation seems to-activate enhancers in TF-networks
while it de-activates enhancers for developmental processes
[72] or, in other words, enhancer and promoter methylation
seem to act in an antagonistic fashion for both types of
processes. A more simplistic interpretation of partly
decoupled expression and methylation assumes rarely or
non-overlapping sets of ‘passenger’ genes regulated by TFs
and/or epigenetic ‘drivers’ such as the IDH-mutation [26].
On a cellular level, our results support a multi-
component approach underpinned by single-cell tran-
scriptome characteristics [59] that indicates variable
composition of the tumors regarding healthy astrocyte-
and oligodendrocyte-like cells, microglia/macrophage
and proliferative stem cell-like constituents as illustrated
in the right part of Fig. 5a. The TME of the subtypes is
characterized by marked variations of the immune cell
composition that overlays with methylation changes of
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their genomes. It suggests an epigenetically-mediated
interplay between tumor cells and immune cells in the
TME.
We found footprints of previously published expression
and methylation gene signatures extracted from studies on
WHO grade II, III and IV gliomas in the tumors studied
here indicating a considerable overlap of molecular mecha-
nisms between LGG and GBM [8] in agreement with previ-
ous studies which underlined relevance of GBM molecular
signatures for LGG [21]. These results support the view
that the molecular heterogeneity of gliomas decomposes
into a set of gene-regulatory modes that were activated in
different combinations and to a varying extent in the indi-
vidual subtypes and in tumors of different grades. In
addition to the G-CIMP and G-CIMP-O signatures that
typically occur in IDH-mut gliomas we also found methyla-
tion characteristics occurring in IDH-wt GBM such as the
RTK II and mesenchymal methylation signatures reflecting
concerted methylation changes of respective groups of
genes in IDH-mut LGG as well (Fig. 5a, part below).
Moreover, we found concerted methylation patterns of the
olfactory subgenome collecting GPCR genes and of
cancer-related keratin intermediate filament genes, respect-
ively. These signatures overlap and combine in different
ways giving rise to diverse methylation and expression
patterns that partly shape the glioma phenotypes.
Phenotypic relatedness suggests developmental paths of
gliomas
For amore detailed view on the relatedness between the sub-
types we performed similarity tree analysis of the molecular
tumor landscapes (Fig. 5b). The expression and methylation
‘phenotypic’ trees obtained differ mainly in the position of
the IDH-wt (C1) subtype. Its expression characteristics show
rather similarities with the C2 tumors because of common
inflammatory and astrocytic signatures while its methylation
profiles rather resemble that of neuronal (C4) tumors owing
to the common lack of the G-CIMP patterns (see the sche-
matic profiles in the lower part of Fig. 5b). On the other hand,
both trees reflect similar mutual relations between the neur-
onal, oligodendroglioma-like (C3) and astrocytoma-like (C2)
tumors where the former two types share similarities mainly
regarding (low) inflammatory, (high) neuronal expression
and (high) GPCR-methylation levels. Degeneration of appar-
ent healthy brain functions in all subtypes, activated
proliferation in C3 and partly inflammation in E3 seem to be
driven by anti-correlated DNA-promoter methylation
changes.
Interestingly, the astrocytoma-like subtypes in C2 sort
in the order E4-E2-E3 and M4-M3-M2, respectively,
which associates with increasing WHO grade of the tu-
mors, their age at first diagnosis, their hazard ratio, the de-
crease of the global methylation levels and of neuronal
expression characteristics and increased senescence by-
pass characteristics. We hypothesize that these trends re-
flect aspects of the progression of astrocytoma like
gliomas from earlier to later phases in the natural course
of the disease [2, 8]. Interestingly, these trends also suggest
increasing therapy resistance along the proneural-
to-mesenchymal axis after comparison with resistance and
inflammatory signatures derived from GBM [54]. Search
for glioma subtypes and/or molecular characteristics most
suitable for immunotherapies is a challenge [43]. The in-
flammatory subtype E3 with maximum M2-macrophage
polarization could be of interest for therapies targeting gli-
oma associated macrophages [10].
Importantly, decreasing total methylation decomposes
into reduced methylation of the GPCR- and keratin-
methylation patterns on one hand, and the G-CIMP pat-
tern, which shows the opposite trend in M4–M3, on the
other hand (Fig. 5b, part below). The relative reduction
of G-CIMP in M2 is compatible with the observation
that while IDH-mut associated G-CIMP initiates glioma-
genesis it seems not required for later clonal expansions
[39]. Interestingly, the RTKII-signature originally obtained
from WHO grade IV IDH-wild type gliomas shows paral-
lels with the senescence bypass signature in IDH-mutated
LGG, and particularly reflects differences between Chr1p/
19q-codeleted and –non-codeleted tumors. Both, loss and
gain of methylation take place in parallel in different re-
gions of the genome of tumor cells and/or in different cel-
lular constituents of the TME. The subtype E5 manifests
characteristics of early stages of astrocytoma-like tumors
such as high levels of the GPCR- and keratin-methylation
patterns and low levels of the G-CIMP-methylation in
addition to the expression of cancer testis genes. E5 col-
lects both, Chr1p/19q-non-codeleted (mainly grade II)
and, to a less amount, Chr1p/19q-codel tumors, which
suggests that mechanisms affecting DNA methylation act
partly independent of the Chr1p/19q-codel status.
(See figure on previous page.)
Fig. 5 Schematic summary: a The major glioma subtypes arise after specific genetic hits. The tumor phenotypes are then shaped by the tumor
microenvironment (TME), its cell composition, epigenetics and additional genetic defects. Different methylation patterns develop in a subtype
specific fashion upon tumor progression (left part). On a cellular level, astrocyte-like and oligodendrocyte-like gliomas are both primarily composed of
proliferating stem cells, oligodendrocytes and astrocytes, however in different amounts, which associates with different immune cell compositions in
the TME and metabolic expression signatures, which partly are affected by methylation effects. b Phenotypic trees provide similarity relations between
the expression and methylation subtypes (top), which were simplified as one-dimensional sequences of subtypes and associated with selected
transcriptional programs, methylation patterns and prognosis (bottom)
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Aberrant methylation shapes glioma phenotypes
Gliomas are consistently characterized by the loss of
neuronal expression signature, especially in IDH-wt and
IDH-mut astrocytoma-like, and to a less degree, also in
oligodendroglioma-like tumors, paralleled by decreasing
expression and hyper-methylation of PRC2-targets with
possible consequences for senescence bypass mecha-
nisms. The latter properties are hallmarks of CIMP-like
subtypes observed in colon cancer and lymphoma and in
grade IV glioma [27, 38]. Previous studies have proposed
a role for PRC2 genes in protecting neurons against de-
generation by repressing aberrant transcriptional pro-
grams [61]. Stratification of repressed chromatin states in
fetal and adult brain revealed an antagonistic methylation
pattern between oligodendroglioma-like (C3) and IDH-wt
gliomas and an intermediate pattern in astrocytoma-like
(C2) tumors which suggests deregulation of developmen-
tal cellular programs in IDH-wt; and of programs of dif-
ferentiated tissue in C3 and partly also in C2. The
former effect associates with the activation of inflamma-
tion and mesenchymal characteristics while the second
one seems to activate proliferation and oxphos metabol-
ism. Epigenetic activation of otherwise suppressed cellular
programs seems to be essential for glioma development
and diversification into subtypes.
Our methylation analysis uses integral methylation
beta-values of upstream regions of each gene which are as-
sumed to reflect mean promoter methylation levels. Similar
methylation patterns were found in extended upstream re-
gions, in the gene body and also for CpG-related signatures,
which all together suggests that DNA-methylation affects
widespread genomic regions in a similar fashion. On the
other hand, this integral methylation analysis eventually
overlooks local and CpG-specific methylation effects with
possible impact for transcriptional regulation. In this con-
text, our integral method should be judged as one limitation
of this study. We expect that alternative methods will
further improve our understanding of the role of
DNA-methylation, e.g., to better resolve the regulatory
element landscapes and transcription factor networks [72]
in gliomas. Also the possible impact of methylation of the
olfactory subgenome on cell function and glioma develop-
ment remains partly unclear and requires future work.
Conclusions
Our study demonstrates the importance of molecular
subtyping of LGG as a concept to better understand the
biology of this disease. We hereby follow a holistic ap-
proach which is guided by previous findings that diffuse
gliomas can be further divided into epigenomic subtypes
that differ in their biology with impact for treatment and
prognosis beyond the WHO classification and histo-
pathological grade. IDH mutated astrocytoma-like LGGs
constitute the most heterogeneous sub-entity, which
stratifies into distinct transcriptomic and methylation
subtypes with possible impact for clinics, e.g. for identifi-
cation of treatment resistant or sensitive tumor strata.
Analogies between astrocytoma-like LGG with grade IV
IDH-wt tumors regarding varying treatment resistance
suggest similar disease mechanisms; however further
studies are required for verification. Hereby epigenetics,
and particularly, DNA methylation is a shaping and driv-
ing factor of glioma heterogeneity and progression. Gen-
omic, epigenetic and transcriptomic factors act in
concert but partly also in a decoupled fashion what un-
derpins the need for integrative, multidimensional sub-
typing of LGG by combining these data on gene and
cellular levels in order to delineate mechanisms of gene
(de-)regulation and to enable better patient stratification
for individualization of treatment.
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